Evaluation of 3-Month Data for the Use of Erenumab for Chronic Migraine in Glasgow

A 3-month audit of erenumab for chronic migraine prevention in Glasgow showed promising results. Data from 93 patients (86% female) revealed that 81% continued treatment due to significant reductions in headache days or severity. Previous treatments included various prophylactics, Botox, and neuromodulation. Side effects were reported in some patients, with constipation being the most common (23%). The study concluded that erenumab had a high response rate at 3 months, but 12-month data are needed to confirm the long-term efficacy.